ACADIA Pharmaceuticals Inc. – NASDAQ:ACAD

Add to watchlist

$24.97

+8.02

+47.32%

Market open

Closed in about 1 hour

-4.62%

month

-4.62%

quarter

-46.65%

year

Market Cap	2.78B
Enterprise value	2.87B

P/E	-13.4
EV/Sales	5.56
EV/EBITDA	-14.04
Price/Sales	5.66
Price/Book	7.31
PEG ratio	0.48
EPS	-0.01

Revenue	813.80M
EBITDA	2.58M
Income	-1.71M
Revenue Q/Q	73.75%
Revenue Y/Y	56.43%

Profit margin	-41.76%
Oper. margin	-43.23%
Gross margin	98.03%
EBIT margin	-43.23%
EBITDA margin	0.32%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Profit margin
Jun 2023	165.23M	1.11M	0.67%
Sep 2023	211.69M	-65.17M	-30.79%
Dec 2023	231.04M	45.79M	19.82%
Mar 2024	205.83M	16.55M	8.04%

ACADIA Pharmaceuticals Financials Estimate

Q Y

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Analyst Estimates
Mar 2024	205.83M	16.55M	8.04%
Sep 2025	274.7M	58.27M	21.22%
Oct 2025	273.2M	26.65M	9.76%
Dec 2025	278.4M	44.98M	16.16%

Analysts Price target
Financials & Ratios estimates

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Debt to assets
Jun 2023	642769000	246.97M	38.42%
Sep 2023	632540000	270.36M	42.74%
Dec 2023	748956000	317.20M	42.35%
Mar 2024	855103000	391.05M	45.73%

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Cash Flow
Jun 2023	8.20M	-194.28M	5.47M
Sep 2023	-58.95M	34.11M	12.75M
Dec 2023	85.38M	-347K	5.43M
Mar 2024	29.07M	-14.03M	1.04M

ACADIA Pharmaceuticals alternative data

ACADIA Pharmaceuticals
Employees

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Employee count
Aug 2023	540
Sep 2023	540
Oct 2023	540
Nov 2023	540
Dec 2023	580
Jan 2024	580
Feb 2024	580
Mar 2024	597
Apr 2024	597
May 2024	597
Jun 2024	610
Jul 2024	610

ACADIA Pharmaceuticals
Hedge Funds Holdings Q1 2023

100.00% 0.00%

of ACAD is owned by hedge funds

144 -76

hedge funds hold ACAD stock

48.52M -107.13M

shares is hold by hedge funds

ACAD hedge funds holdings changes

ACADIA Pharmaceuticals
Insider Trading

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Insider trades (number of shares)
Period	Buy	Sel
Dec 2023	0	2000
Jan 2024	0	5053
Feb 2024	0	7447
Mar 2024	0	28288
Apr 2024	0	33648
May 2024	0	19733
Jun 2024	0	975
Aug 2024	0	51014
Nov 2024	0	24661

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	19 Nov 2024	TEEHAN BRENDAN officer: EVP, COO, HEAD OF COMMERCIAL officer: EVP, COO, HEAD OF COMM..	Common Stock	10,329	$16.81	$173,630
Sale	19 Nov 2024	KIHARA JAMES officer: PRINCIPAL ACCOUNTING OFFICER officer: PRINCIPAL ACCOUNTING O..	Common Stock	4,073	$16.81	$68,467
Sale	19 Nov 2024	SCHNEYER MARK C. officer: EVP, CHIEF FINANCIAL OFFICER officer: EVP, CHIEF FINANCIAL O..	Common Stock	10,259	$16.81	$172,454
Option	17 Nov 2024	TEEHAN BRENDAN officer: EVP, COO, HEAD OF COMMERCIAL officer: EVP, COO, HEAD OF COMM..	Common Stock	9,913	N/A	N/A
Option	17 Nov 2024	TEEHAN BRENDAN officer: EVP, COO, HEAD OF COMMERCIAL officer: EVP, COO, HEAD OF COMM..	Common Stock	9,913	N/A	N/A
Option	17 Nov 2024	TEEHAN BRENDAN officer: EVP, COO, HEAD OF COMMERCIAL officer: EVP, COO, HEAD OF COMM..	Restricted Stock Units	9,913	N/A	N/A
Option	17 Nov 2024	KIHARA JAMES officer: PRINCIPAL ACCOUNTING OFFICER officer: PRINCIPAL ACCOUNTING O..	Common Stock	3,965	N/A	N/A
Option	17 Nov 2024	KIHARA JAMES officer: PRINCIPAL ACCOUNTING OFFICER officer: PRINCIPAL ACCOUNTING O..	Common Stock	3,965	N/A	N/A
Option	17 Nov 2024	KIHARA JAMES officer: PRINCIPAL ACCOUNTING OFFICER officer: PRINCIPAL ACCOUNTING O..	Restricted Stock Units	3,965	N/A	N/A
Option	17 Nov 2024	SCHNEYER MARK C. officer: EVP, CHIEF FINANCIAL OFFICER officer: EVP, CHIEF FINANCIAL O..	Common Stock	9,913	N/A	N/A

ACAD insider trading transactions

ACADIA Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Compounds, salts thereof and methods for treatment of diseases Filling date: 20 Aug 2018 Issue date: 13 Sep 2022	20 Aug 2018	13 Sep 2022
Application	Application SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES Filling date: 14 Sep 2021 Issue date: 4 Aug 2022	14 Sep 2021	4 Aug 2022
Application	Application FORMULATIONS OF PIMAVANSERIN Filling date: 14 Mar 2022 Issue date: 23 Jun 2022	14 Mar 2022	23 Jun 2022
Application	Application METHODS OF TREATING PAIN WITH A THIAZOLINE ANTI-HYPERALGESIC Filling date: 3 Nov 2021 Issue date: 2 Jun 2022	3 Nov 2021	2 Jun 2022
Grant	Grant Utility: Compounds, salts thereof and methods for treatment of diseases Filling date: 21 Feb 2020 Issue date: 31 May 2022	21 Feb 2020	31 May 2022
Application	Application Compounds for Pain Treatment, Compositions Comprising Same, and Methods of Using Same Filling date: 6 Jul 2021 Issue date: 19 May 2022	6 Jul 2021	19 May 2022
Application	Application METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PH- ENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C Filling date: 16 Mar 2021 Issue date: 27 Jan 2022	16 Mar 2021	27 Jan 2022
Application	Application METHODS OF TREATING DEPRESSION, ANXIETY AND SEXUAL DYSFUNCTION USING THE COMPOUND PIMAVANSERIN Filling date: 30 Oct 2019 Issue date: 20 Jan 2022	30 Oct 2019	20 Jan 2022
Application	Application 5-HT2A SEROTONIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR USE IN REDUCING AMYLOID-BETA PEPTIDES AND ACCUMULATION OF AMYLOID PLAQUES Filling date: 16 Feb 2021 Issue date: 6 Jan 2022	16 Feb 2021	6 Jan 2022
Grant	Grant Utility: Combination of pimavanserin and cytochrome P450 modulators Filling date: 15 Nov 2019 Issue date: 7 Dec 2021	15 Nov 2019	7 Dec 2021

ACAD patents

ACADIA Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 27 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 3 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript

ACAD earnings call transcripts

ACADIA Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Stephen R. Davis J.D. (1961) Chief Executive Officer & Director	64	$1,230,000
Dr. Srdjan R. Stankovic (1957) Pres	68	$1,120,000
Mr. Austin D. Kim (1964) Executive Vice President, Gen. Counsel & Sec.	61	$626,760

ACADIA Pharmaceuticals
Latest News

Thursday, 19 December 2024
16:05	Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025	businesswire.com
Monday, 16 December 2024
16:05	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Wednesday, 11 December 2024
16:05	Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million	businesswire.com
Monday, 9 December 2024
09:00	Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer	businesswire.com
Tuesday, 3 December 2024
10:55	Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term	zacks.com
Wednesday, 27 November 2024
15:18	Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET	seekingalpha.com
11:11	ACAD Signs License Deal With Saniona for Rights to Neurology Drug	zacks.com
Tuesday, 26 November 2024
16:05	Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711	businesswire.com
Thursday, 21 November 2024
16:05	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences	businesswire.com
Friday, 15 November 2024
16:05	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Tuesday, 12 November 2024
10:56	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock	zacks.com
Monday, 11 November 2024
10:50	Acadia Pharmaceuticals: Proving The Naysayers Wrong	seekingalpha.com
Thursday, 7 November 2024
11:05	Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth	zacks.com
Wednesday, 6 November 2024
20:09	ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript	seekingalpha.com
18:21	Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates	zacks.com
Tuesday, 5 November 2024
16:05	Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million	businesswire.com
Wednesday, 30 October 2024
11:07	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release	zacks.com
Thursday, 17 October 2024
18:41	Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024	businesswire.com
Wednesday, 16 October 2024
16:07	Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome	businesswire.com
Monday, 14 October 2024
13:11	Why Acadia (ACAD) Could Beat Earnings Estimates Again	zacks.com
Wednesday, 9 October 2024
12:48	ACAD or TECH: Which Is the Better Value Stock Right Now?	zacks.com
Tuesday, 8 October 2024
16:05	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Thursday, 26 September 2024
16:05	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Monday, 23 September 2024
16:15	Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals	businesswire.com
Thursday, 19 September 2024
12:00	Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals	businesswire.com
Thursday, 5 September 2024
12:37	Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?	zacks.com
Wednesday, 28 August 2024
16:05	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences	businesswire.com
Monday, 26 August 2024
15:02	Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again	seekingalpha.com
Wednesday, 14 August 2024
08:04	Ryan Reynolds Announces More to Parkinson's® Campaign	businesswire.com
Wednesday, 7 August 2024
09:21	Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues	zacks.com

Ideas & Opinions

Seeking Alpha 28 Jul 2025

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In
Seeking Alpha 17 May 2025

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview
Seeking Alpha 23 Jun 2024

Acadia Pharmaceuticals: Back In The Buy Zone
Seeking Alpha 14 Jun 2024

Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Seeking Alpha 6 Jun 2024

Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments
Seeking Alpha 23 Jan 2024

Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Seeking Alpha 13 Dec 2023

Acadia Pharmaceuticals: Legal Overhang On Nuplazid Removed
Seeking Alpha 10 Dec 2023

Acadia's Daybue: A Small Patient Pool Making Big Waves
Seeking Alpha 26 Sep 2023

Acadia Pharmaceuticals: Difficult Market Masks Progress
Seeking Alpha 23 Sep 2023

Daybue Drives Acadia Pharmaceuticals To Positive Earnings (Rating Upgrade)

Frequently Asked Questions (FAQ)

What's the price of ACADIA Pharmaceuticals stock today?

One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $24.97.
When is ACADIA Pharmaceuticals's next earnings date?

Unfortunately, ACADIA Pharmaceuticals's (ACAD) next earnings date is currently unknown.
Does ACADIA Pharmaceuticals pay dividends?

No, ACADIA Pharmaceuticals does not pay dividends.
How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals has a market capitalization of 2.78B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 40.45% to 726.44M US dollars.
What is ACADIA Pharmaceuticals's stock symbol?

ACADIA Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "ACAD".
What is ACADIA Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of ACADIA Pharmaceuticals?

Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are ACADIA Pharmaceuticals's key executives?
ACADIA Pharmaceuticals's management team includes the following people:
- Mr. Stephen R. Davis J.D. Chief Executive Officer & Director(age: 64, pay: $1,230,000)
- Dr. Srdjan R. Stankovic Pres(age: 68, pay: $1,120,000)
- Mr. Austin D. Kim Executive Vice President, Gen. Counsel & Sec.(age: 61, pay: $626,760)
How many employees does ACADIA Pharmaceuticals have?

As Jul 2024, ACADIA Pharmaceuticals employs 610 workers, which is 2% more then previous quarter.
When ACADIA Pharmaceuticals went public?

ACADIA Pharmaceuticals Inc. is publicly traded company for more then 21 years since IPO on 27 May 2004.
What is ACADIA Pharmaceuticals's official website?

The official website for ACADIA Pharmaceuticals is acadia-pharm.com.
Where are ACADIA Pharmaceuticals's headquarters?

ACADIA Pharmaceuticals is headquartered at 12830 El Camino Real, San Diego, CA.
How can i contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals's mailing address is 12830 El Camino Real, San Diego, CA and company can be reached via phone at 858 558 2871.

ACADIA Pharmaceuticals Inc.

acadia-pharm.com

Exchange:

NASDAQ

Full time employees:

620

Industry:

Biotechnology

Sector:

Healthcare

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

858 558 2871

12830 El Camino Real
San Diego, CA 92130

CIK: 0001070494
ISIN: US0042251084
CUSIP: 004225108